Forget Antibodies. Use Aptamers!™
Terms & Conditions

Advancing Aptamer Applications™


  • Target SpecificallyKnown BIOMARKERS AND Discover UNKNOWN Biomarkers (new!)
  • CELL-targeting Aptamer Ligands
  • TISSUE-targeting for Delivery
  • Molecular-Beacon Aptamers for Diagnostic Kit Detection (new!)
Click for R&D Inquiry
Antibody problems? Have difficult targets to develop effective ligands or antibodies?
What if an antibody doesn't exist for your target or antigen? No problem. Let Aptagen provide you with an alternative - the aptamer. You've heard about this new technology. Now, try it.

HIGH Affinity. HIGH Specificity.
Contact Us today for details.

Apta-beacons™A novel (one-step) approach to detect analytes in virtually any sample type (such as serum). Aptagen's engineering capabilities include: allosteric ribozymes, molecular switches, and molecular beacons.

  1. Large dynamic range of sensitivity.
  2. No need for the cumbersome multi-step approach of ELISA assays.

Apta-beacon Technical Bulletin. PDF (608KB)


Click for R&D Inquiry
What is an aptamer?  A stable DNA, RNA, or peptide that binds with high affinity and specificity to targets such as small organics, peptides, proteins, cells, and tissues.  For example, search our Apta-Index™ (Aptamer Database).

Unlike antibodies, some aptamers exhibit stereoselectivity. In addition, aptamers (synthetic antibodies) have been generated that exhibit greater than 10,000-fold binding affinity for theophylline over caffeine, which differ from one another in structure by only a single methyl group.

Synthetic Antibodies - The Emerging Field of Aptamers.PDF (706KB)


Click for R&D Inquiry

What is an aptamer?

Aptamers (synthetic antibodies) are (stable) single-stranded DNA, RNA, or peptide molecules capable of binding to its target antigen with high affinity and specificity. Aptamers (synthetic antibodies) have been developed against a wide variety of targets ranging from small organics to large proteins.


  • Manufacturing costs and time are all lower compared to that of monoclonal antibody production.
  • Once the aptamer (nucleic acid) sequence is known, the aptamer (synthetic antibody) can be produced on the fly using an oligo synthesizer to meet ones immediate needs.
  • Easy to label with reporters, enzymes, or fluorescent tags.
  • Cost Benefit Comparison of Antibodies and Aptamers. PDF (97.3KB) 

Aptamers Against Virtually Any Target!

Proteins.      Organics.      Toxins.


Diagnostic and Biomarker Detection. PDF (215KB)
Forget Antibodies. Use Aptamers. PDF (213KB)


Click for R&D Inquiry

Using the current antibody method; for every drug that makes it to market, hundreds of promising candidates that worked in-vitro (on the lab bench) fail during animal ADMET studies (absorption, distribution, metabolism, excretion, and toxicity). From lab bench to pharmacy shelves it takes from seven to fifteen years and costs $4B with an average failure rate of 80%. Half of this time and approximately 70% of all associated biopharmaceutical R&D costs are spent on in-vitro development.

Because aptamers (synthetic antibodies) are an in-vivo (directly tested in the animal model) approach, they avoid the majority of the bench testing, saving several years and approximately 35% of the R&D cost. The unique chemistry of aptamers, unlike other forms of drugs currently used, permits the natural selection of drug candidates in whole animal models, bypassing the test tube entirely. By using an animal model with the disease state of interest, Aptagen need not possess specific knowledge of the pathology or disease condition in question. As an added benefit, because this approach reduces the false starts, there are actually fewer animals needed for drug evaluation.

Contact Us to schedule a webinar.


Drug Discovery

Click for R&D Inquiry

Aptagen's rapid fast-track approach to drug discovery bypasses the 'test tube' in pre-clinical development, taking it one step closer to human clinical trials.

In Vitro Assays  ----->  In Vivo Studies  ------>  Clinical Trials

The Problem: Drug candidates that prove positive in "test tube" (or in vitro) assays may face substantial problems when tested in animals, a necessary prerequisite before human clinical trials. These problems include absorption, distribution, metabolism, excretion, and toxicity.

The Solution: Aptagen's technique, involving molecules called aptabodies™ (patent pending), overcomes the limitation of the traditional pharmaceutical drug discovery process. The unique chemistry of aptabodies™, unlike other forms of drugs currently used, permits the selection of drug candidates in whole animal models, bypassing the "test tubes" entirely, and taking drug development one step closer to human clinical trials. By using an animal model with the disease state of interest, specific knowledge of the pathology or disease condition is not needed. An added benefit is the significant reduction in the number of animals needed for drug evaluation before entering into human clinical trials.

BENEFITS: overcome delivery issues * * identify unknown biomarkers * * tailor PK/PD properties * * rescue failed drug candidates from targeting/specificity issues

On average, only one in a thousand drug candidates make it to human clinical trials.
Spending too much time and capital on the trial-and-error approach to Drug Discovery? On average, only one in a thousand drug candidates make it to human clinical trials. The cost and time associated with the traditional method of drug development is expensive and quite slow (7 to 15 years and almost $1 Billion). However, Aptagen's technology significantly reduces the unpredictability, cost, and time for drug discovery and development.

Drug Discovery

Over a century ago, Paul Ehrlich described the ideal drug, famously known as a 'magic bullet,' in which it specifically targets the disease site and would not harm healthy tissue. However, finding these magic bullets with drug-like properties involves a trial and error approach and is extremely slow. Aptagen has developed the concept of a ‘replicating magic bullet’ called an aptabody™. The aptabody™ technology has a shorter development time compared to traditional methods of drug development, and can be used to increase the specificity and improve delivery of existing drug compounds resulting in the next generation of pharmaceuticals with improved pharmacodynamics and pharmacokinetics.


Contact us for more information on how we can solve your drug pipeline needs.

Serving over 50 Companies, Organizations, and Universities globally.

Bio Rad Biogen Idec Cephalon Covidien GE Genetech Harvard IBM Md. Anderson Cancer Center Medimmune Merck Nestle Penn State